ERSEUS 1996, Perseus’ first fund, was formed in 1996 with $35 million in capital commitments to invest in undervalued and growth equity transactions. This fund is fully invested.

PERSEUS CAPITAL, L.L.C. was formed in 1997 with $102 million in capital commitments with a focus on distressed companies, growth equity capital for healthcare companies, and some venture opportunities. This fund is fully invested.

PERSEUS ACQUISITION/RECAPITALIZATION FUND, L.L.C. is a co-investment/club fund that was formed in 1999 to participate in larger distressed, growth equity, buyout, and recapitalization transactions of operating companies, frequently alongside other Perseus funds. This fund, which invested an aggregate $77 million, has reached its termination date and is no longer making new investments.

PERSEUS 2000, L.L.C. was formed in 2000 with $222 million in capital commitments to focus on undervalued growth equity, venture, and small buyout opportunities mainly in the healthcare and energy, environmental, and engineering technology industries. This fund is fully invested.

PERSEUS MARKET OPPORTUNITY FUND, L.P. closed in 2004 with $340 million of committed capital to pursue control or undervalued distressed and growth equity investments with a particular emphasis on transactions involving undervalued publicly traded companies. This fund is fully invested.

PERSEUS 2000 EXPANSION, L.L.C., which was formed in 2004, is a $153 million fund used primarily for follow-on investments for Perseus 2000 and other small undervalued and growth equity transactions. This fund is fully invested.

PERSEUS PARTNERS VII, L.P., established in 2006, is a $602 million fund focused on control investments in undervalued middle market growth equity and distressed transactions principally in the following industries: healthcare; energy, environmental, and engineering technologies; and branded consumer products. More than 90% of this fund’s capital has been committed or reserved.

PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP, which was jointly founded by Perseus and Soros Private Fund Management, L.L.C. in 2000 with $449 million in capital commitments, focuses on investments in life science companies developing biopharmaceutical products and/or creating businesses based on advanced life science technologies. This fund is fully invested.